Investing.com — Straumann (SIX:) has posted 15.1% growth in organic sales in the first quarter, topping analyst expectations, but shares in the dental implants manufacturer were dented after it flagged softening U.S. operations.
The Swiss firm, which specializes in researching, developing and making technologies for tooth replacements and other orthodonotic solutions, said revenue during the three-month period rose to 643.8 million Swiss francs.
Solid momentum in China helped fuel a spike revenues in Asia-Pacific. Organic growth of 82% in the region was far better than consensus estimates of 51.3%, analysts at Stifel noted.
“The implant business was the main driver and both premium and value (challenger) brands were strong,” they added.
However, sales slowed to 3.7% in North America when excluding currency effects and acquisitions, down from 7.2% in the corresponding period in 2023 — a trend that Straumann said was due to a weaker market for dental implants in the U.S.
Shares plunged by more than 11% in European trading on Tuesday.
